Venx-201 -

Disclaimer: This article is for informational purposes only and does not constitute medical advice. VENX-201 is an investigational drug not yet approved by the FDA or any regulatory authority. Clinical trial data are subject to change as research progresses.

CAPS are rare, monogenic autoinflammatory diseases caused by gain-of-function mutations in the NLRP3 gene. Patients suffer from recurring fever, urticarial rash, joint pain, and, in severe cases, aseptic meningitis and sensorineural hearing loss. VENX-201

Before moving into human trials, VENX-201 underwent rigorous preclinical validation. Studies published in abstracts from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) demonstrated the following: Disclaimer: This article is for informational purposes only